Dai Horiuchi, PhD
Assistant Professor, Pharmacology; Feinberg School of Medicine
Research Program
- Translational Research in Malignancy (TRIM)
Cancer-Focused Research
Our research aims to identify and validate novel therapeutic strategies to significantly lower the mortality rates associated with triple-negative breast cancer (TNBC), which represents one of the breast cancer subtypes with
the poorest clinical outcome. Triple-negative (TN) tumors present serious clinical challenges due to limited insights into the mechanisms by which the tumors occur and progress to become clinically unmanageable diseases, and due to lack of validated therapeutic targets. We are devoted to uncovering the vulnerabilities of TN tumors and preclinically validating novel therapeutic concepts, setting the foundation for early stage human
clinical studies.